Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.

Published online

Journal Article

Adjuvants have a critical role for improving vaccine efficacy against many pathogens, including HIV. Here, using transcriptional RNA profiling and systems serology, we assessed how distinct innate pathways altered HIV-specific antibody responses in nonhuman primates (NHPs) using 8 clinically based adjuvants. NHPs were immunized with a glycoprotein 140 HIV envelope protein (Env) and insoluble aluminum salts (alum), MF59, or adjuvant nanoemulsion (ANE) coformulated with or without Toll-like receptor 4 (TLR4) and 7 agonists. These were compared with Env administered with polyinosinic-polycytidylic acid:poly-L-lysine, carboxymethylcellulose (pIC:LC) or immune-stimulating complexes. Addition of the TLR4 agonist to alum enhanced upregulation of a set of inflammatory genes, whereas the TLR7 agonist suppressed expression of alum-responsive inflammatory genes and enhanced upregulation of antiviral and interferon (IFN) genes. Moreover, coformulation of the TLR4 or 7 agonists with alum boosted Env-binding titers approximately threefold to 10-fold compared with alum alone, but remarkably did not alter gene expression or enhance antibody titers when formulated with ANE. The hierarchy of adjuvant potency was established after the second of 4 immunizations. In terms of antibody durability, antibody titers decreased ∼10-fold after the final immunization and then remained stable after 65 weeks for all adjuvants. Last, Env-specific Fc-domain glycan structures and a series of antibody effector functions were assessed by systems serology. Antiviral/IFN gene signatures correlated with Fc-receptor binding across all adjuvant groups. This study defines the potency and durability of 8 different clinically based adjuvants in NHPs and shows how specific innate pathways can alter qualitative aspects of Env antibody function.

Full Text

Duke Authors

Cited Authors

  • Francica, JR; Zak, DE; Linde, C; Siena, E; Johnson, C; Juraska, M; Yates, NL; Gunn, B; De Gregorio, E; Flynn, BJ; Valiante, NM; Malyala, P; Barnett, SW; Sarkar, P; Singh, M; Jain, S; Ackerman, M; Alam, M; Ferrari, G; Salazar, A; Tomaras, GD; O'Hagan, DT; Aderem, A; Alter, G; Seder, RA

Published Date

  • November 28, 2017

Published In

Volume / Issue

  • 1 / 25

Start / End Page

  • 2329 - 2342

PubMed ID

  • 29296883

Pubmed Central ID

  • 29296883

International Standard Serial Number (ISSN)

  • 2473-9529

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2017011411

Language

  • eng

Conference Location

  • United States